Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MABp1 [XILONIX] in patients with advanced non-small cell lung cancer

Trial Profile

MABp1 [XILONIX] in patients with advanced non-small cell lung cancer

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Bermekimab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2015 Positive results from subset of patients are published in Investigational New Drugs journal and are available online, according to XBiotech company media release.
    • 22 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top